- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02872805
Adolescent to Adult Patient-centered HIV Transition (ADAPT) Study (ADAPT)
December 21, 2023 updated by: Vicki Tepper, University of Maryland, Baltimore
One of the distinct challenges faced by emerging adults with HIV is the transition of their care from their long-term pediatric HIV provider to treatment within an adult HIV program.
The consequences of an unsuccessful transition can range from difficult to catastrophic.
The Adolescent to Adult Patient-centered HIV Transition (ADAPT) Study is a prospective cohort trial of an innovative intervention targeting gaps in care that are major drivers of loss in the ART continuum of care cascade among adolescents and increasing missed opportunities to engage adolescents into care.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The specific aims of ADAPT are: 1.
To inform strategies for transition services in resource-limited settings; 2. To examine the developmental, clinical, and other factors that predict a successful transition; and, 3. To gain fundamental insight on implementation barriers among African adolescents through the application of the ego-network defined social support that will inform targets for structured intervention.
ADAPT will be conducted in central, southern, and northern Nigeria at selected PEPFAR sites supported by the Institute of Human Virology, Nigeria.
To address Aim 1 the investigators will conduct six focus groups including: Adolescent patients, parents and health care providers.
To address aim 2, the investigators will conduct a cluster randomized clinical trial.
The two interventions are based on prior evidence-informed engagement strategies: 1) educational interventions and 2) interventions that use a peer transition advocate who prepares the adolescent and their parents for transition.
The investigators will enroll 300 patients (150 patients in each arm).
The sites will be assigned to either the intervention arm or a control arm.
The primary outcome will be successful transition, keeping two follow-up appointments within a nine months period following transition.
Secondary outcomes, as recommended by focus group participants will also be measured.
To examine the potential role of social network components and characteristics of both egos and alters on primary outcomes, a Generalized Estimating Equation (GEE) approach will be used to explore the associations between primary outcomes and factors at the ego, alter, and network levels.
The finding from this study will guide institution of best practices for transitioning adolescents in Nigeria and other countries lower and middle income countries with similar challenges and potential for high impact.
Study Type
Interventional
Enrollment (Actual)
298
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
FCT
-
Abuja, FCT, Nigeria
- Institute of Human Virology, Nigeria
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 19 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- HIV infected patients between the ages of 16-19 years of age
- Patients who have been in care at the study site facility for a minimum of 1 year
- Patients who plan to transition their HIV care to one of the selected study sites
- Patients who are able to provide informed consent
Exclusion Criteria:
- HIV infected patients who have significant cognitive impairments(e.g., Mental retardation)
- Patients planning to transition their HIV care outside the selected study facilities
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PEPFAR Enhanced Standard of Care (PESCA)
This arm reflects an enhanced standard of care comparison group for PEPFAR supported sites.
We will provide standardized materials to be used by current clinical staff to help support whatever the site specific activities are related to transition from pediatric to adult medical care
|
Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
Other Names:
|
Experimental: Peer Transition Advocate (PTA)
The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors.
They will engage patients in role-plays to simulate appointments in adult practices.
The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care.
PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients.
PTA will support counseling and testing services for adolescents within the facilities.
For those perinatally-infected, important care and support services include disclosure and stigma issues.
|
The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors.
They will engage patients in role-plays to simulate appointments in adult practices.
The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care.
PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients.
PTA will support counseling and testing services for adolescents within the facilities.
For those perinatally-infected, important care and support services include disclosure and stigma issues.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful transition
Time Frame: 9 months after transition occurs
|
ADAPT focuses on a service primary outcome, successful transition, which is defined as two consecutive kept appointments at the designated adult clinic within 9 months of transition
|
9 months after transition occurs
|
Viral load suppression
Time Frame: 12 months after transition occurs
|
viral load (VL)<400 at 12 months post-transition
|
12 months after transition occurs
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Vicki J Tepper, Ph.D., University of Maryland, Baltimore
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2019
Primary Completion (Actual)
December 20, 2023
Study Completion (Actual)
December 21, 2023
Study Registration Dates
First Submitted
August 16, 2016
First Submitted That Met QC Criteria
August 16, 2016
First Posted (Estimated)
August 19, 2016
Study Record Updates
Last Update Posted (Actual)
December 22, 2023
Last Update Submitted That Met QC Criteria
December 21, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- HP-00070099
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on PEPFAR Enhanced Standard of Care (PESCA)
-
Massachusetts General HospitalActive, not recruiting
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... and other collaboratorsCompleted
-
Rhode Island HospitalUniversity of Mississippi Medical CenterRecruitingHIV PreventionUnited States
-
Children's Hospital Medical Center, CincinnatiUniversity of DelawareRecruitingObesity, ChildhoodUnited States
-
University of Colorado, DenverCompletedCancer, Lung | Cancer, Head and NeckUnited States
-
Susan M KieneNational Institute of Mental Health (NIMH); Makerere University; University of... and other collaboratorsCompleted
-
VA Office of Research and DevelopmentUniversity of Wisconsin, MadisonActive, not recruitingTobacco Dependence | VeteransUnited States
-
University of ArkansasActive, not recruitingHIV/AIDS | Pre-exposure ProphylaxisUnited States
-
Harvard School of Public Health (HSPH)Elton John AIDS Foundation; Management and Development for Health, Tanzania; Comic...CompletedPregnancy | Mother-to-child Transmission of HIVTanzania